文献速递药物不良反应与药物警戒

草药不良反应信号:基于范围综述的证据与文档分析

Signals of Adverse Reactions to Herbal Medicines: Evidence and Document Analysis Based on a Scoping Review.
PubMed 文献 · Drug Saf · 2025-07-02

该研究基于已发表范围综述,分析10,861个药物不良反应信号中53个涉及草药(均来自病例报告),并评估这些信号在欧美官方文档中的记录一致性。结果显示多数文档一致(73%),但消费者标签信息明显不足,提示需加强监管以确保草药危害信息全面传达给美国消费者。

要点

  • 范围综述中仅0.49%信号涉及草药,且全部基于病例报告。
  • 欧美文档对草药不良反应信号的一致性达73%,但仍有27%不一致。
  • 美国消费者标签中仅20%提及专业文档中已有的不良反应。

核心结论

  • 涉及草药的不良反应信号极少且均基于病例报告。
  • 欧美官方文档信息总体一致,但部分信号存在差异。
  • 美国消费者标签信息不全,可能需加强监管。

研究设计与样本

  • 基于已发表范围综述的二次分析,纳入10,861个药物不良反应信号。
  • 按ATC分类识别草药(V90),并检索欧美专业及消费者文档。
  • 描述性总结,比较欧美文档及美国专业与消费者文档间的一致性。

主要发现

  • 10,861个信号中53个(0.49%)涉及草药,全部基于病例报告。
  • 37个信号有欧美双方文档,其中73%一致,27%不一致。
  • 不一致中6个仅见于美国文档,3个仅见于欧盟专论,1个美国警告而欧盟未警告。
  • 当专业文档未收录不良反应时消费者标签也未收录;当收录时仅20%消费者标签提及。

临床怎么用

  • 临床应关注草药不良反应信号的病例报告来源。
  • 处方或咨询时需注意欧美文档间的不一致信息。
  • 不应仅依赖美国消费者标签获取草药不良反应信息。

局限性

  • 所有信号均基于病例报告,证据等级有限。
  • 仅纳入范围综述已覆盖的信号,可能存在遗漏。
  • 文档一致性判断依赖主观分类标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To date, signals of adverse reactions to herbal medicines have not been systematically reviewed, limiting pharmacovigilance of herbal medicines because of a lack of data. OBJECTIVES: We sought to analyse the available evidence on signals involving herbal medicines and to determine to what extent they had been documented at the European Union (EU) level and in the USA. METHODS: We used the results of a published scoping review of interventional and non-interventional studies that reported signals of adverse reactions to drugs. We assigned Anatomical Therapeutic Chemical classification to all drugs, and identified herbal medicines when they fell under the Anatomical Therapeutic Chemical V90. We ascertained the presence of the adverse reaction, or related adverse reactions, for each signal in reference documents for healthcare professionals: the US Botanical Safety Handbook and the EU monographs and US Dietary Supplement Fact Sheets; and in those for consumers: the US Dietary Supplement Label Database. We summarised the data descriptively, treating US documents as one and comparing harms across pairs of US and EU documents by signal. Documents were deemed concordant if they both included the same or related adverse reactions, or if neither did. We also compared adverse reactions across US documents for healthcare professionals with those for consumers. RESULTS: Of the 10,861 signals covered by the scoping review, 53 (0.49%) concerned herbal medicines, all based on case reports. Reference documents from both the US and EU were available for 37 signals. Most of the documents were concordant (73%), and ten (27%) were discordant: six adverse reactions were mentioned only in US documents, three only in EU monographs, and one was warned against in US documents but not in EU documents. Twenty-one signals could be followed up in the Botanical Safety Handbook and Dietary Supplement Fact Sheets. Most (68%) US documents for healthcare professionals were concordant. When the Botanical Safety Handbook and Dietary Supplement Fact Sheets did not include an adverse reaction, neither did the Dietary Supplement Label Database. However, when they did, only 20% of the labels for consumers did too. The proportion of labels mentioning adverse reactions otherwise available in documents intended for healthcare professionals ranged widely, reflecting differences across multiple labels for the same products. CONCLUSIONS: Very few signals of adverse reactions from the wider scoping review concerned herbal medicines, and were all based on case reports. Information was mostly concordant across documents in the EU and USA. As manufacturers are solely responsible for the contents of the Dietary Supplement Label Database, regulatory oversight may be required to ensure that consistent and comprehensive information on the harms of herbal medicines is made available to consumers in the USA. In this study we looked at how adverse effects (side effects) of herbal medicines are reported in official documents in the USA and the European Union (EU). We used data from a previous review of studies of medicinal drugs to select those that reported signals, i.e. possible associations of herbal medicines with adverse effects. We then checked if the adverse effects were listed in official documents for healthcare professionals and consumers in the two regions. We also checked the adverse effects in US documents for healthcare professionals matched with those in product labels for US consumers. We found 29 studies in which 53 signals of adverse effects to herbal medicines were mentioned, all of which were based on anecdotal case reports. Of the 37 signals for which documents were available in both the USA and the EU, most had matching information about adverse effects, but about a quarter did not: some adverse effects were mentioned only in US documents, others only in EU ones. US documents for healthcare professionals were mostly consistent, but product labels mentioned fewer adverse effects in comparison. This suggests that consumers may not always be getting all relevant information on the possible adverse effects of herbal medicines. To sum up, possible adverse effects of herbal medicines are probably being under-reported. Stronger regulation may be needed to make sure that product labels for herbal medicines give consumers complete information on possible adverse effects.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Sartori D, Aronson JK, Brand JS, et al. Signals of Adverse Reactions to Herbal Medicines: Evidence and Document Analysis Based on a Scoping Review. Drug Saf. 2025. PMID: 40601107. doi:10.1007/s40264-025-01580-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。